Rep. Julie Johnson Sells Off Shares of Bristol Myers Squibb Company (NYSE:BMY)

Representative Julie Johnson (D-Texas) recently sold shares of Bristol Myers Squibb Company (NYSE:BMY). In a filing disclosed on September 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Bristol Myers Squibb stock on August 14th. The trade occurred in the Representative’s “CHASE BROKERAGE ACCOUNT (3935)” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of McDonald’s (NYSE:MCD) on 8/14/2025.
• Sold $1,001 – $15,000 in shares of Eli Lilly and Company (NYSE:LLY) on 8/14/2025.
• Sold $1,001 – $15,000 in shares of Arthur J. Gallagher & Co. (NYSE:AJG) on 8/14/2025.
• Sold $1,001 – $15,000 in shares of Parker-Hannifin (NYSE:PH) on 8/14/2025.
• Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 8/14/2025.
• Sold $1,001 – $15,000 in shares of Fidelity National Information Services (NYSE:FIS) on 8/14/2025.
• Sold $1,001 – $15,000 in shares of ConocoPhillips (NYSE:COP) on 8/14/2025.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 8/14/2025.
• Sold $1,001 – $15,000 in shares of Dover (NYSE:DOV) on 8/14/2025.
• Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 8/14/2025.

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock opened at $45.56 on Friday. The stock’s fifty day moving average is $46.97 and its two-hundred day moving average is $49.83. The company has a market capitalization of $92.74 billion, a PE ratio of 18.37, a price-to-earnings-growth ratio of 2.36 and a beta of 0.35. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb Company has a 52 week low of $42.96 and a 52 week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The business had revenue of $12.27 billion for the quarter, compared to the consensus estimate of $11.32 billion. During the same quarter in the prior year, the company earned $2.07 EPS. The business’s revenue was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be given a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.4%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio is 100.00%.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the transaction, the executive vice president directly owned 167,379 shares of the company’s stock, valued at approximately $7,922,048.07. This represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.09% of the company’s stock.

Analyst Ratings Changes

BMY has been the topic of a number of recent research reports. Morgan Stanley reissued a “hold” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Daiwa Capital Markets downgraded Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target on the stock. in a research report on Tuesday, August 5th. Citigroup dropped their price target on Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating on the stock in a research report on Friday, August 1st. Wall Street Zen cut Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 6th. Finally, Daiwa America cut Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $56.38.

Institutional Investors Weigh In On Bristol Myers Squibb

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. raised its stake in Bristol Myers Squibb by 42.4% in the second quarter. Osaic Holdings Inc. now owns 689,531 shares of the biopharmaceutical company’s stock valued at $33,371,000 after buying an additional 205,325 shares during the last quarter. Total Investment Management Inc. purchased a new stake in Bristol Myers Squibb in the second quarter valued at about $38,000. MASTERINVEST Kapitalanlage GmbH purchased a new stake in Bristol Myers Squibb in the second quarter valued at about $3,752,000. Silverlake Wealth Management LLC raised its stake in Bristol Myers Squibb by 4.8% in the second quarter. Silverlake Wealth Management LLC now owns 5,835 shares of the biopharmaceutical company’s stock valued at $270,000 after buying an additional 269 shares during the last quarter. Finally, TT Capital Management LLC purchased a new stake in Bristol Myers Squibb in the second quarter valued at about $349,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.